Core Viewpoint - Sanara MedTech Inc. reported preliminary financial results for Q4 and full year 2025, indicating strong growth and provided financial guidance for 2026, projecting continued revenue growth driven by surgical products [1][4]. Financial Results - Preliminary net revenue for Q4 2025 is expected to be between $27.2 million and $27.7 million, reflecting a year-over-year increase of approximately 3% to 5% compared to $26.3 million in Q4 2024 [5]. - For the full year 2025, net revenue is projected to be in the range of $102.7 million to $103.2 million, marking a growth of approximately 19% compared to $86.7 million in 2024 [5]. - Excluding BIASURGE sales from Q4 2024, the adjusted net revenue for Q4 2025 is expected to increase by approximately 11% to 13% year-over-year [5][13]. Financial Guidance - The company anticipates full year 2026 net revenue to range from $116 million to $121 million, representing growth of approximately 13% to 17% compared to the midpoint of the expected net revenue for 2025 [4][6]. - The growth in 2026 is expected to be primarily driven by sales of soft tissue products [6]. Operational Highlights - The company secured a new contract with Vizient, enhancing access to BIASURGE products at contracted pricing, effective January 1, 2026 [4][6]. - Sanara plans to introduce the OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. market in Q1 2027, pending FDA clearance [5][6]. Cash and Debt Position - As of December 31, 2025, the company reported cash of approximately $16.6 million and long-term debt of $46.0 million, compared to cash of $15.9 million and long-term debt of $30.7 million as of December 31, 2024 [5].

Financial Data and Key Metrics Changes - Worldwide revenue for Q2 2025 was $48.6 million, representing a growth of 21.7% year-over-year [30] - U.S. revenue was $46.4 million, reflecting a growth of 22.8% [31] - Adjusted EBITDA was positive at $1 million, compared to an adjusted EBITDA loss of $2.7 million in the prior year [34] - Net loss narrowed to $6.2 million or $0.14 per diluted share, compared to a net loss of $8.9 million or $0.22 per diluted share in the prior year [34] - Cash and marketable securities increased to $145.5 million, marking the first quarter of cash flow breakeven [35] Business Line Data and Key Metrics Changes - U.S. procedure volume increased by 25%, with double-digit growth across all modalities [10][32] - The physician base grew by 25%, reaching a record of 1,440 U.S. physicians performing procedures [22] - Average territory productivity reached $2.1 million, representing a 23% increase year-over-year [25] Market Data and Key Metrics Changes - International revenue was $2.2 million, impacted by delayed regulatory clearance for iFuse Torque in Europe [32] - The company expects iFuse Torque to boost revenue growth in Europe starting in 2026 [32] Company Strategy and Development Direction - The company aims to expand its platform of solutions targeting challenging procedures, improving surgical outcomes with lower failure rates [6][8] - Focus on innovation, physician engagement, commercial execution, and operational excellence as key priorities [12] - Plans to launch new products targeting outpatient settings and expand into new addressable markets [21][86] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand across the portfolio and the effectiveness of their strategy [44] - The company anticipates continued growth driven by strong physician engagement and product adoption [80] - Guidance for full-year revenue was updated to $195 million to $198 million, implying year-over-year growth of approximately 17% to 18% [36] Other Important Information - The company achieved cash flow breakeven ahead of schedule, indicating potential for consistent positive free cash flow [35] - Leadership changes were announced, with Tony Recoupero retiring and Nicholas Kerr promoted to Chief Commercial Officer [27][28] Q&A Session Summary Question: Guidance on top line growth and assumptions for the second half - Management highlighted strong first-half performance and confidence in continued demand, with a sequential decline expected in Q3 due to seasonality [40][46] Question: Gross margin guidance and pricing pressure - Management discussed maintaining gross margin guidance at 78.5% to 79%, embedding assumptions for ASP pressure while acknowledging potential for better-than-expected outcomes [51][56] Question: Growth of interventional doctors using products - Management noted strong growth from interventional doctors and the potential for further engagement with new product launches [60][62] Question: International market contribution and torque rollout in Europe - Management expressed optimism about the torque product's impact in Europe, with expectations for growth in 2026 [95] Question: Capital deployment priorities - Management indicated a focus on continued investment in R&D and commercial initiatives while maintaining a strong cash position [98]

Core Insights - MiMedx Group, Inc. will participate in several industry conferences this quarter to showcase its Advanced Wound Care and Surgical Solutions [1][2] - The company aims to highlight its commitment to innovation and the scientific evidence supporting its products at these conferences [2] Conference Participation - MiMedx will be featured at the Diabetic Limb Salvage (DLS) Conference from April 10-12, 2025, in Washington, D.C., where it will host a sponsored lunch symposium [3] - The company will also participate in the Symposium on Advanced Wound Care (SAWC) Spring 2025 from April 30 to May 4, 2025, in Grapevine, TX, with another sponsored lunch symposium [3] - Additionally, MiMedx will present at Digestive Disease Week (DDW) 2025 from May 3-6, 2025, in San Diego, CA, focusing on the use of amniotic tissues in colorectal surgery [4] Company Overview - MiMedx is recognized as a leader in providing solutions for chronic and hard-to-heal wounds, with a vision to be the leading global provider of healing solutions through innovation [4] - The company has over a decade of experience in the wound care, burn, and surgical sectors of healthcare [4] Conference Details - The DLS Conference emphasizes a multidisciplinary approach to wound healing and limb salvage, featuring an international faculty and promoting evidence-based practices [5] - The SAWC serves as a forum for the entire wound care team to connect and improve patient outcomes through education and advanced clinical reviews [6] - DDW is the largest international gathering in gastroenterology and related fields, showcasing over 4,400 abstracts and hundreds of lectures on the latest advances [7]